Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab PRO Evaluation in Ankylosing Spondylitis (Real-World, Prospective Observational)
ChiCTR2600127221Phase 4Completed
- Sponsor
- Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in ankylosing spondylitis (AS), sponsored by Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Primary endpoints: ASAS20 response rate, ASAS40 response rate and 1 more. Started Jun 2026; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2600127221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127221.